Charles River aims to reduce CGT timelines with LLV tech

Charles River Laboratories has introduced the Lentivation lentiviral vector (LVV) manufacturing platform, which it says can reduce timelines for CGTs by 60%.

According to the contract development manufacturing organization (CDMO), the platform can cut manufacturing timelines for cell and gene therapies (CGTs) by up to 60%, resulting to less than seven months compared to the usual 18 months when using traditional production workflows.

In addition, Ramin Baghirzade, senior director, global head commercial, Gene Therapy CDMO Services, Charles River  told BioProcess Insider its Lentivation platform has the following advantages:

DepositPhotos/denisismagilov

Lentivation has been designed to meet customer needs for both clinical and commercial supply. The firm said it uses its screening toolbox to tackle complex gene-of-interest plasmids, phase-appropriate production, on-hand materials, in-house analytics, and off-the-shelf (OTS) LVV packaging plasmids.

“Charles River’s LVV platform provides a streamlined, reliable path for therapeutic developers to clinic and commercial. The proven platform builds on Charles River’s established capabilities and processes, fine-tuned over decades spent successfully supporting advanced therapy clients,” said Beth Tebeau, site director, Rockville, Charles River.

The addition of Lentivation aims to support the company’s other available technologies, including its nAAvigation platform that was launched in October 2022.

“There has been 10+ landmark commercial gene therapy approvals and the industry is at an inflection point. With a maturing market, we’ve recognized an increased need for standardization and platform approaches. This is the latest in a series of Charles River’s platforms and innovations being offered to the market,” said Baghirzade.